Biological Research Laboratories, Nissan Chemical Industries Ltd., 1470 Shiraoka, Minamisaitama, Saitama, Japan.
Br J Pharmacol. 2010 Apr;159(7):1418-28. doi: 10.1111/j.1476-5381.2009.00630.x. Epub 2010 Mar 3.
It is not clear if the new 3-hydroxyl-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor pitavastatin prevents atherogenesis by a direct effect. Statins have a cholesterol-lowering effect, so an accessible animal model of atherosclerosis showing only moderate hypercholesterolaemia as in humans, is needed. The effects of pitavastatin were evaluated on atherosclerotic lesions accumulating foam cells derived from macrophages, produced in rabbits with moderate hypercholesterolaemia by chronic inhibition of nitric oxide synthase (NOS).
White New Zealand rabbits were fed a 0.2% cholesterol diet with the NOS inhibitor N(omega)-nitro-L-arginine methyl ester (L-NAME) in the same diet. Pitavastatin (0.1 and 0.3 mg x kg(-1)) was given orally once a day for 8 weeks. The aortic arch and thoracic aorta were analysed by histochemistry and atherosclerotic lesions were quantified. The effect of pitavastatin on adhesion of THP-1 cells to endothelial cells, and cholesterol content in RAW264.7 cells incubated with oxidized or acetylated LDL were also investigated.
Atherosclerotic lesions containing foam cells were induced in a model of atherosclerosis in rabbits with moderate hypercholesterolaemia by chronic inhibition of NOS. The area of atherosclerotic lesions was diminished by pitavastatin administration. The adhesion of THP-1 cells and cholesteryl ester content in RAW macrophages were decreased by pitavastatin treatment.
Atherosclerosis induced by chronic inhibition of NOS in moderately hypercholesterolaemic rabbits was suppressed by pitavastatin via inhibition of macrophage accumulation and macrophage foam cell formation.
目前尚不清楚新型 3-羟基-3-甲基戊二酰辅酶 A(HMG-CoA)还原酶抑制剂匹伐他汀是否通过直接作用来预防动脉粥样硬化形成。他汀类药物具有降低胆固醇的作用,因此需要一种可用于研究的动物模型,该模型可显示出与人中度高脂血症相似的仅中度高胆固醇血症,同时易于发生动脉粥样硬化。本研究评估了匹伐他汀对泡沫细胞形成的影响,这些泡沫细胞源自慢性抑制一氧化氮合酶(NOS)诱导的中度高胆固醇血症兔的巨噬细胞。
将新西兰白兔喂饲含 0.2%胆固醇的饮食,并在饮食中添加 NOS 抑制剂 N(ω)-硝基-L-精氨酸甲酯(L-NAME)。同时,给予兔口服匹伐他汀(0.1 和 0.3mg·kg-1),每天 1 次,共 8 周。采用组织化学方法分析主动脉弓和胸主动脉,并对动脉粥样硬化病变进行定量分析。还研究了匹伐他汀对 THP-1 细胞与内皮细胞黏附的影响,以及氧化型或乙酰化 LDL 孵育的 RAW264.7 细胞中胆固醇含量的影响。
通过慢性抑制 NOS,在中度高胆固醇血症兔中诱导出含有泡沫细胞的动脉粥样硬化病变。匹伐他汀给药可使动脉粥样硬化病变面积减小。匹伐他汀处理可降低 THP-1 细胞黏附及 RAW 巨噬细胞中胆固醇酯含量。
通过慢性抑制 NOS,在中度高胆固醇血症兔中诱导的动脉粥样硬化可被匹伐他汀抑制,其机制可能与抑制巨噬细胞聚集和泡沫细胞形成有关。